Drug intelligence / Profile preview

SER-262

Development stage: Phase 1
Lead developer: Seres Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

SER-262 is an investigational, orally administered, synthetically-derived microbiome therapeutic developed by Seres Therapeutics. It consists of a rationally-designed consortium of twelve bacterial strains in spore form and is manufactured without the need for human donor material. [2] SER-262 was designed to restore the gut microbiome to treat primary *Clostridioides difficile* infection (CDI). [2] It was the first synthetically-derived microbiome therapeutic to enter clinical trials, with a Phase 1b study initiated in July 2016. [2] While Seres Therapeutics' pipeline has advanced other candidates like VOWST (SER-109) for recurrent CDI and SER-155 for transplant-related infections, SER-262 is no longer featured as an active program in the company's public pipeline. [1, 5]

Beyond the preview

Go deeper on SER-262.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-262.

Explore the full profile